<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04248790</url>
  </required_header>
  <id_info>
    <org_study_id>TaiwanUPrEPU</org_study_id>
    <secondary_id>MOST 108-2636-B-006-004</secondary_id>
    <nct_id>NCT04248790</nct_id>
  </id_info>
  <brief_title>Design and Development of a Mobile App to Improve Adherence to Pre-exposure Prophylaxis in Men Who Have Sex With Men</brief_title>
  <official_title>Design and Development of a Mobile App to Improve Adherence to Pre-exposure Prophylaxis in Men Who Have Sex With Men: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng Kung University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Tsing Hua University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cheng Kung University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is testing feasibility and acceptability of a theoretically based mobile&#xD;
      application (app), UPrEPU, to increase adherence to pre-exposure prophylaxis (PrEP) among men&#xD;
      who have sex with men (MSM) to prevent human immunodeficiency virus (HIV).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to develop an effective mobile application (app), UPrEPU to recognize the&#xD;
      factors and decisions that affect PrEP adherence in high-risk populations to improve PrEP&#xD;
      adherence. Key components of the app include a sex/PrEP diary using ecological momentary&#xD;
      assessment to facilitate accurate data collection; PrEP taking reminder; HIV and sexually&#xD;
      transmitted infections (STI) testing information and reminders; HIV and PrEP information and&#xD;
      videos; geo-location.&#xD;
&#xD;
      After eligible PrEP candidates agree to participate in the study, we will ask participants to&#xD;
      install the app. Then, we will begin to collect their sexual diary and PrEP taking log via&#xD;
      ecological momentary assessment. Participants will also complete monthly assessments. The&#xD;
      monthly follow-up will test HIV/STI and drug concentration. The participants will be&#xD;
      interviewed for difficulties when they use our app and giving feedback on it.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 25, 2020</start_date>
  <completion_date type="Actual">October 23, 2020</completion_date>
  <primary_completion_date type="Actual">October 23, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Usability</measure>
    <time_frame>4 months</time_frame>
    <description>Scores on system usability scale (SUS) for this app at the first month and the fourth month.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility: data based on the app analytics</measure>
    <time_frame>4 months</time_frame>
    <description>Frequency of app log-in;&#xD;
Use of app components such as PrEP-taking and sex behavior reports;&#xD;
Duration of app use</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of adherence monitoring</measure>
    <time_frame>4 months</time_frame>
    <description>Measuring the Tenofovir (TDF) and Emtricitabine (FTC) drug concentration in dried blood spot (DBS) samples to compare with self-report data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility: data from qualitative interviews</measure>
    <time_frame>4 months</time_frame>
    <description>any technical challenges participants may have encountered;&#xD;
recommendations for the app improvement;&#xD;
users' satisfaction and comfort in using this app</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>HIV Infections</condition>
  <condition>Pre-Exposure Prophylaxis</condition>
  <arm_group>
    <arm_group_label>Experimental: the mobile App</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the intervention arm will receive access to all the app capabilities. The app features include information on HIV testing locations, sex and PrEP diary and reminder of taking PrEP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>mobile app to improve adherence to PrEP self-management</intervention_name>
    <description>Access to the mobile app which includes the sex and PrEP diary, information on HIV/STI testing, PrEP reminders and geo-location features.</description>
    <arm_group_label>Experimental: the mobile App</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Male.&#xD;
&#xD;
          -  Aged 20 or above.&#xD;
&#xD;
          -  Resides in Taiwan and able to understand, read, and speak Mandarin Chinese.&#xD;
&#xD;
          -  Remains HIV negative prior to and during the study period.&#xD;
&#xD;
          -  The results of the laboratory tests are eligible to initiate PrEP.&#xD;
&#xD;
          -  Currently taking PrEP or willing to initiate PrEP.&#xD;
&#xD;
          -  Reports having 4 times or above anal sex with men in the past month.&#xD;
&#xD;
          -  Owns an Android or Apple operating system (iOS) smartphone and willing to download the&#xD;
             study app.&#xD;
&#xD;
          -  Willing to wear the device we provided during the study period.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  With abnormal kidney function (creatinine clearance rate â‰¦ 60 mL/minute).&#xD;
&#xD;
          -  Currently on medication that might interact with PrEP, such as drugs contain&#xD;
             lamivudine in the pre-PrEP assessment.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol Strong, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cheng Kung University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan City</city>
        <state>Tainan</state>
        <zip>701</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei city hospital (Renai Branch)</name>
      <address>
        <city>Taipei</city>
        <zip>10629</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>December 28, 2020</last_update_submitted>
  <last_update_submitted_qc>December 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cheng Kung University</investigator_affiliation>
    <investigator_full_name>Carol Strong</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT04248790/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

